Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement C5

Complement C5

Brief Information

Name:Complement C5
Target Synonym:C5a,Complement Component 5,ECLZB,Anaphylatoxin C5a Analog,C5a Anaphylatoxin,C5b,C5,Prepro-C5,CPAMD4,Complement C5,C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4,C5D
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CO5-H52Hx-ELISA
Human Complement C5 (R885H), His TagHuman Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) ELISA bioactivity

Immobilized Human Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

CO5-H52H7-ELISA
Human Complement C5 (w917s), His TagHuman Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) ELISA bioactivity

Immobilized Human Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) at 2 μg/mL (100 μL/well) can bind Anti-C5a MAb (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

Customer Reviews

Synonym Name

Complement C5,C5,CPAMD4

Background

Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Eculizumab 5G1-1; HAL-1; LEX-98; h-5G1.1 Approved Alexion Pharmaceuticals Inc Soliris Mainland China Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal Alexion Europe Sas 2007-03-16 Neuromyelitis Optica; Macular Degeneration; Diabetes Mellitus; Kidney Failure, Chronic; Thrombocytopenia; Guillain-Barre Syndrome; Urea Cycle Disorders, Inborn; Asthma; Glomerulonephritis, Membranoproliferative; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Hemolytic-Uremic Syndrome; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Rejection of organ transplantation; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; End Stage Liver Disease; Rejection of renal transplantation; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; HELLP Syndrome Details
Ravulizumab ALXN-1810; ALXN-1210 Approved Alexion Pharmaceuticals Inc, Xencor Inc Ultomiris United States Myasthenia Gravis Alexion Pharmaceuticals Inc 2018-12-21 Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Dermatomyositis; Glomerulonephritis, IGA; Coronavirus Disease 2019 (COVID-19); Atypical Hemolytic Uremic Syndrome; Thrombotic Microangiopathies; Lupus Nephritis; Respiratory Distress Syndrome, Adult; Neuromyelitis Optica; Pneumonia, Viral; Acute Lung Injury; Amyotrophic Lateral Sclerosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ALXN-5500 ALXN-5500 Phase 1 Clinical Alexion Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (IBC GENERIUM) Phase 3 Clinical Ibc Generium Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
eculizumab biosimilar(Isu Abxis) Phase 1 Clinical Isu Abxis Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Nomacopan EV-576; rVA576; rEV-576 Evolutec Details
CAN-106 CAN-106 Phase 2 Clinical Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn Details
BDB-001 BDB-001; BDB001; BDB 001; BDB-1 Phase 2 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Hidradenitis Suppurativa Details
Eculizumab biosimilar (Biocad) BCD-148 Biocad Details
Avacincaptad pegol ARC-187; ARC-1905 Archemix Details
Vilobelimab CaCP-29; IFX-1 Phase 3 Clinical Inflarx Nv Shock, Septic; Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Drug-Related Side Effects and Adverse Reactions; Microscopic Polyangiitis; Pyoderma Gangrenosum; Sepsis; Coronavirus Disease 2019 (COVID-19); Lung Diseases, Interstitial; Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome Details
Eculizumab biosimilar (Amgen) ABP-959 Phase 3 Clinical Amgen Inc Hemoglobinuria, Paroxysmal Details
Zilucoplan RA-101495-SC; RA-101495 Phase 3 Clinical Ucb Sa, Ra Pharma Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases; Amyotrophic Lateral Sclerosis Details
Gefurulimab TPP-2511; ALXN-1720; CON-9978 Phase 1 Clinical Alexion Pharmaceuticals Inc Proteinuria Details
Pozelimab REGN-3918 Phase 3 Clinical Regeneron Pharmaceuticals Inc Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies Details
Cemdisiran ALN-62643; ALN-CC5; AD-62643 Phase 3 Clinical Alnylam Pharmaceuticals Inc Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Atypical Hemolytic Uremic Syndrome Details
Crovalimab SKY-59; RG-6107; CH-7092230; RO-7092230; RO-7112689; RO-7112689/F01 Phase 3 Clinical F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Anemia, Sickle Cell Details
P-014 P014; KP-104 Phase 2 Clinical Kira Pharmaceuticals LLC Hemoglobinuria, Paroxysmal Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message